Payment overview · 2025
General Payments
$1,547.38
68 reported records · 24 companies
Healthcare provider profile · identity verified
Simmanjeet Mangat, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NIAGARA FALLS, NY · NPI 1275832412
Verified facts
What the public records show
CMS Open Payments records show Simmanjeet Mangat, MD received $1,547.38 in general payments during 2025 across 68 reported records.
GlaxoSmithKline, LLC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $233.21 | 15.1% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $216.39 | 14.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.31 | 11.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.05 | 6.3% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $93.84 | 6.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $93.60 | 6.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.65 | 5.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.45 | 5.7% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $75.74 | 4.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.14 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.85 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.06 | 2.5% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $32.80 | 2.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.70 | 2.0% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.47 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.38 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.96 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.50 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.63 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.11 | 1.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.39 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.85 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.23 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,547.38 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $216.39 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $188.16 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.65 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $98.05 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $93.84 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $93.60 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.65 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.45 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.28 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $49.14 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.05 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.05 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.70 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
164 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
149 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 190 |
| Gabapentin | Gabapentin | 430 | 97 |
| Lisinopril | Lisinopril | 398 | 127 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 336 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 68 |
| Metformin Hcl | Metformin Hcl | 262 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 66 |
| Omeprazole | Omeprazole | 229 | 69 |
| Furosemide | Furosemide | 223 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 211 | 59 |
| Famotidine | Famotidine | 184 | 45 |
| Ibuprofen | Ibuprofen | 169 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 164 | 41 |
| Trulicity | Dulaglutide | 149 | 32 |
| Metformin Hcl Er | Metformin Hcl | 140 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 40 |
| Jardiance | Empagliflozin | 127 | 38 |
| Ezetimibe | Ezetimibe | 125 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 31 |
| Losartan Potassium | Losartan Potassium | 109 | 34 |
| Potassium Chloride | Potassium Chloride | 109 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 29 |
| Trazodone Hcl | Trazodone Hcl | 105 | 35 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 99 | 28 |
| Ozempic | Semaglutide | 94 | 22 |
| Montelukast Sodium | Montelukast Sodium | 90 | 22 |
| Farxiga | Dapagliflozin Propanediol | 88 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Eliquis | Apixaban | 80 | 19 |
| Alendronate Sodium | Alendronate Sodium | 77 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 66 | 18 |
| Spironolactone | Spironolactone | 64 | 16 |
| Alprazolam | Alprazolam | 63 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 15 |
| Carvedilol | Carvedilol | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 33 |
| Glipizide Er | Glipizide | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 14 |
| Azithromycin | Azithromycin | 52 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 14 |
| Simvastatin | Simvastatin | 48 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 20 |
| Glipizide | Glipizide | 45 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Baclofen | Baclofen | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 17 |
| Methylprednisolone | Methylprednisolone | 40 | 36 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Bumetanide | Bumetanide | 37 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 14 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Clotrimazole | Clotrimazole | 29 | 14 |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 28 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | 12 |
| Naproxen | Naproxen | 26 | 11 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 14 |
| Nystatin | Nystatin | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,547.38 · 68 records | GlaxoSmithKline, LLC. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Fluad, Flucelvax, KRYSTEXXA, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, Omnipod, Ozempic, QULIPTA, QUTENZA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, WATCHMAN FLX, YUPELRI, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error